Clinical and Economic Analysis of Secukinumab in Patients with Ankylosing Spondylitis
The aim of the study: To evaluate clinical and economic advisability of the use of secukinumab in the therapy of ankylosing spondylitis (AS) compared to golimumab, infliximab, certolizumab pegol and etanercept. Materials and methods: A cost-effectiveness analysis of the compared drugs in patients with AS was conducted. The measure of effectiveness was the share of patients with ASAS 20 in 12-24 and 96-104 weeks of therapy. Expected costs of 2 years of the drug therapy of AS were calculated. For each drug, the incremental cost-effectiveness ratio compared with placebo was defined based on the results of clinical trials. Results: After 2 years treatment, Secukinumab had the lowest ICER (1.875 million RUB per patient with ASAS 20 response) compared to the other studied drugs. Secukinumab was also the cheapest among all compared drugs: the cost of 2 years of its administration was 1.080 million RUB (1.121-3.308 million RUB for the same period in case of the other drugs). Conclusion: The treatment of patients with AS with Secukinumab is clinically and economically advisable because of its high clinical efficiency and the lowest costs of two years of therapy. It also has the lowest cost-effectiveness ratio compared to placebo among other biologic agents.